1q21.3
Showing 1 - 25 of >10,000
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Active, not recruiting
- Acute Lymphoblastic Leukemia
- +15 more
- Laboratory Biomarker Analysis
- +3 more
-
Chicago, Illinois
- +2 more
Jan 12, 2023
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis, Recurrent Acute Myeloid Leukemia Trial in New York
Completed
- Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 11, 2021
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia Trial in United States
Completed
- Acute Myeloid Leukemia
- +19 more
- Allogeneic Hematopoietic Stem Cell Transplantation
- +8 more
-
Lewes, Delaware
- +16 more
Aug 3, 2022
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11,
Active, not recruiting
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- +5 more
- Biopsy
- +7 more
-
Lewes, Delaware
- +42 more
Mar 15, 2022
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
AML, Adult Trial (Biological characterization of AML with MECOM or atypical 3q26 rearrangements)
Not yet recruiting
- AML, Adult
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- (no location specified)
Apr 21, 2023
Endometrial Cancer Trial in Oklahoma City (Pembrolizumab, Vaginal cuff brachytherapy (VCB), Paclitaxel)
Recruiting
- Endometrial Cancer
- Pembrolizumab
- +3 more
-
Oklahoma City, OklahomaStephenson Cancer Center
Jan 9, 2023
COVID-19 Prevention Trial in Louisville (Q-Griffithsin 3.0, Q-Griffithsin 6.0)
Recruiting
- COVID-19 Prevention
- Q-Griffithsin 3.0
- Q-Griffithsin 6.0
-
Louisville, KentuckyUniversity of Louisville Clinical Trials Unit
Jun 28, 2022
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) Trial in United
Completed
- Adult Acute Basophilic Leukemia
- +16 more
-
Little Rock, Arkansas
- +53 more
Jan 13, 2022
Diabetic Foot, Chronic Osteomyelitis, Septic Arthritis Trial in Geneva (Histones H3.1 blood levels)
Recruiting
- Diabetic Foot
- +2 more
- Histones H3.1 blood levels
-
Geneva, SwitzerlandUniversity Hospitals Geneva
Oct 22, 2022
DNA Samples From Acute Lymphoblastic Leukemia or Acute Myeloid
Completed
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- +8 more
- Laboratory Biomarker Analysis
-
Philadelphia, PennsylvaniaChildrens Oncology Group
Jul 12, 2022
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b) Trial
Completed
- Adult Acute Megakaryoblastic Leukemia (M7)
- +13 more
- Sirolimus
- +2 more
-
Philadelphia, PennsylvaniaThomas Jefferson University
Feb 2, 2023
Osteo-arthritis Trial in Aberystwyth (Q-actin, Placebo)
Recruiting
- Osteo-arthritis
- Q-actin
- Placebo
-
Aberystwyth, Ceredigion, United KingdomWell-being and Health Assessment Research Unit (WARU)
May 24, 2023
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic
Completed
- Adult Acute Megakaryoblastic Leukemia (M7)
- +15 more
- trebananib
- +3 more
-
Buffalo, New York
- +1 more
Sep 8, 2022
Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia Trial in United States (Cytarabine,
Active, not recruiting
- Acute Myeloid Leukemia
- +9 more
- Cytarabine
- +4 more
-
Brewer, Maine
- +8 more
Jun 18, 2021
Squamous Cell Carcinoma of Larynx Trial in São Paulo (carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v.
Recruiting
- Squamous Cell Carcinoma of Larynx
- carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
- +2 more
-
São Paulo, BrazilBeneficiencia Portuguesa de São Paulo/Hospital São José
Dec 22, 2022
Triple Negative Breast Cancer Trial in Guangzhou (Gemcitabine and carboplatin plus antibiotic (moxifloxacin), Gemcitabine
Recruiting
- Triple Negative Breast Cancer
- Gemcitabine and carboplatin plus antibiotic (moxifloxacin)
- Gemcitabine combined with carboplatin plus placebo
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 6, 2022
Pediatric Celiac Disease Index: CELIAC-Q KIDS
Active, not recruiting
- Celiac Disease in Children
- +2 more
- Interview and scale development
-
Hamilton, Ontario, Canada
- +1 more
Nov 2, 2022
Electronic Cigarette Use, Retina; Change Trial in Montréal (RETI-port/scan 21, Zilia Ocular, OCT-A)
Recruiting
- Electronic Cigarette Use
- Retina; Change
- RETI-port/scan 21
- +2 more
-
Montréal, Quebec, CanadaÉcole d'optométrie de l'Université de Montréal
Apr 3, 2023
Drug Interaction Trial in Uppsala (Drug Drug Interaction)
Recruiting
- Drug Interaction
- Drug Drug Interaction
-
Uppsala, SwedenCTC Clinical Trial Consultants AB
Apr 13, 2023
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) Trial in Atlanta,
Terminated
- Adult Acute Basophilic Leukemia
- +16 more
- eltrombopag olamine
- standard follow-up care
-
Atlanta, Georgia
- +1 more
Jul 20, 2022
Influenza Trial in Toronto, Mirabel, Pointe-Claire (H1 influenza antigen)
Completed
- Influenza
- H1 influenza antigen
-
Toronto, Ontario, Canada
- +2 more
Nov 3, 2023